Real- World Use of Complement Inhibitor Therapy in Critically Ill Children With Thrombotic Microangiopathy: Results From the Spanish Multicenter Matucip Registry.
This retrospective study of 40 critically ill Spanish children with thrombotic microangiopathy treated with complement inhibitors reveals that while half had suspected complement-mediated HUS, the other half received off-label therapy for other subtypes, with non-CM-HUS patients experiencing significantly later treatment initiation, more severe extrarenal manifestations, longer PICU stays, and higher rates of discharge hypertension.